GLP-1 Drugs Beyond Weight Loss: What the Science Says

GLP-1 agonists like Ozempic and Wegovy have revolutionized treatment for diabetes and obesity. However, emerging research suggests these drugs may also address conditions ranging from heart disease to neurodegenerative disorders. While some findings are promising, experts caution that much of the evidence remains preliminary. Here’s a breakdown of what the science currently shows.

How GLP-1 Drugs Work

GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut that regulates insulin release and appetite. GLP-1 agonists mimic this hormone, helping manage weight and blood sugar. Beyond the gastrointestinal tract, GLP-1 receptors are present in the brain, heart and liver, sparking interest in their potential for broader therapeutic applications.

Where the Evidence Is Strong

Cardiovascular Benefits: A trial of 17,000 participants found semaglutide (the active ingredient in Ozempic and Wegovy) reduced the risk of major cardiovascular events by 20%, even in individuals without diabetes. This aligns with findings from the SUSTAIN 6 trial, which demonstrated similar protective effects.

Liver Disease: Semaglutide outperformed a placebo in improving non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, in a trial of 1,200 patients. This reflects results from the STEP trials, which showed significant reductions in liver fat and inflammation.

Sleep Apnea: Tirzepatide (Mounjaro) has been linked to improved sleep apnea symptoms, likely due to weight loss reducing airway pressure. This effect is supported by studies on weight-loss interventions for obstructive sleep apnea.

Cancer: Promising, But Not Proven

Obesity is a known risk factor for 13 cancers, and weight loss from GLP-1 drugs may lower this risk. A study of 86,000 adults with obesity found a 17% reduction in cancer risk among GLP-1 users. However, no large-scale clinical trials have yet confirmed a direct causal link between these drugs and cancer prevention. Early data suggest anti-inflammatory effects may play a role, but more research is needed.

Endometriosis: Early Signs

Small studies, such as a survey of 161 women, indicate GLP-1 drugs may alleviate endometriosis symptoms. This could be due to the presence of GLP-1 receptors in reproductive tissues. However, no randomized controlled trials have been conducted, leaving this area speculative.

Addiction and Mental Health: Mixed Results

Addiction: A large analysis of 1.3 million people found GLP-1 users had lower rates of opioid overdose and alcohol intoxication. Semaglutide also showed promise in reducing alcohol consumption in individuals with